Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 1;107(8):1933-1939.
doi: 10.3324/haematol.2022.280652.

Full versus prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis

Lorenzo Loffredo  1 , Augusto Di Castelnuovo  2 , Giovanni Alfonso Chiariello  3 , Pasquale Pignatelli  4 , Francesco Violi  5
Affiliations
Meta-Analysis

Full versus prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis

Lorenzo Loffredo et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Forrest plots of death and thrombotic events. (A) Forest plots for death and thrombotic events according to the subgroups for full anticoagulation (FA) and prophylactic-intermediate anticoagulation (PIA) doses. (B) Forest plots for death according to the subgroups for FA and PIA doses. (C) Forest plots for arterial and venous and thrombotic events according to the subgroups for FA and PIA doses.
Figure 2.
Figure 2.
Forrest Plots of thrombotic events and bleeding. (A) Forest plots for venous thrombotic events according to the subgroups for full anticoagulation (FA) and prophylactic-intermediate anticoagulation (PIA) doses. (B) Forest plots for arterial thrombotic events. (C) Forest plots for major bleeding events according to the subgroups for FA and PIA doses.
See this image and copyright information in PMC

References

    1. Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Hypercoagulation and antithrombotic treatment in Coronavirus 2019: a new challenge. Thromb Haemost. 2020;120(6):949-956. - PMC - PubMed
    1. Spyropoulos AC, Levy JH, Ageno W, et al. . Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859-1865. - PMC - PubMed
    1. Ortega-Paz L, Galli M, Capodanno D, et al. . Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021. Sep 14. [Epub ahead of print] - PMC - PubMed
    1. Sholzberg M, da Costa BR, Tang GH, et al. . Randomized trials of therapeutic heparin for COVID-19: a meta-analysis. Res Pract Thromb Haemost. 2021;5(8):e12638. - PMC - PubMed
    1. Lopes RD, de Barros ESPGM, Furtado RHM, et al. . Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021;397(10291):2253-2263. - PMC - PubMed

Publication types

Substances